Mild Cognitive Impairment (MCI) is a disorder considered to be a transitional stage from health to dementia. Diagnosis of dementias at these early stages is always troublesome because the pathophysiologic events leading to dementia precede clinical symptoms. Thus, the development of biomarkers that can be used to support the diagnosis of dementias at early stages is rapidly becoming a high priority. We have recently reported the value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease (AD). The aim of this study is to determine whether measuring plasmatic concentration of neurosin is a valuable test to predict progression of MCI.
CITATION STYLE
Menendez-Gonzalez, M., Castro-Santos, P., Calatayud, M., Perez-Piñera, P., Ribacoba, R., Martinez-Rivera, M., … Suarez, A. (2008). Plasmatic level of neurosin predicts outcome of mild cognitive impairment. International Archives of Medicine, 1(1), 11. https://doi.org/10.1186/1755-7682-1-11
Mendeley helps you to discover research relevant for your work.